- Case report
- Open Access
- Open Peer Review
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report
© Lapadula et al; licensee BioMed Central Ltd. 2007
- Received: 15 January 2007
- Accepted: 08 May 2007
- Published: 08 May 2007
This report regards the case of a 43 year-old HIV-positive woman who developed an episode of serious transaminase elevation during stavudine-including antiretroviral therapy. Diagnostic assessment ruled out hepatitis virus co-infection, alcohol abuse besides other possible causes of liver damage. No signs of lactic acidosis were present. Liver biopsy showed portal inflammatory infiltrate, spotty necrosis, vacuoles of macro- and micro-vesicular steatosis, acidophil and foamy hepatocytes degeneration with organelles clumping, poorly formed Mallory bodies and neutrophil granulocytes attraction (satellitosis). A dramatic improvement in liver function tests occurred when stavudine was discontinued and a new antiretroviral regimen with different nucleoside reverse transcriptase inhibitors was used. The importance of considering hepatotoxicity as an adverse event of HAART including stavudine, even in absence of other signs of mitochondrial toxicity should therefore be underlined. Liver biopsy may provide further important information regarding patients with severe transaminase elevation, for a better understanding of the etiology of liver damage.
- Lactic Acidosis
- Nucleoside Reverse Transcriptase Inhibitor
Highly active anti-retroviral therapy (HAART) is associated with a number of serious and potentially life-threatening adverse events, including drug-induced liver injury (i.e., hepatotoxicity – HT). The potential of nucleoside reverse transcriptase inhibitors (NRTI) for liver damage seems to be related to mitochondrial DNA damage and can also lead to lactic acidosis . Although in vitro data demonstrated a prominent mitochondrial oxidative stress in human hepatoma cells exposed to stavudine , and a stronger inhibition of mitochondrial DNA synthesis by dideoxynucleoside analogues (ddX – i.e., stavudine, didanosine and zalcitabine) than by other NRTI , existing studies have failed to demonstrate any consistent association between the use of these drugs and the development of subsequent HT [4, 5]. Their possible causative role is therefore still under debate.
Appropriate investigations were performed to rule out possible causes of liver transaminase elevations. The patient was negative for hepatitis B surface antigen (HBsAg) with a pattern of isolated positive hepatitis B core antibodies (HBcAb). However, plasma HBV-DNA resulted negative. Serum positivity for hepatitis C virus antibodies (HCV-Ab) was reported in May 2001, but chronic HCV infection was excluded by HCV-RNA testing, which resulted undetectable on two consecutive determinations in June and October 2003. Moreover, HCV-RNA was repeated at the time of HT and still resulted negative. Further, hepatitis A virus immunoglobulin M (HAV-IgM) resulted negative and the patient denied any alcohol abuse or concomitant use of other hepatotoxic drugs.
Suspecting a drug-related liver toxicity, IDV/r, the most recently introduced antiretroviral agent, was suspended on February 17th 2004 and replaced by lamivudine (3TC). Liver function monitoring and diagnostic assessment were continued.
On November 10th 2004, antiretroviral drugs were interrupted because of further transaminase elevation and the patient underwent further exams, confirming previous investigations. The patient continued to deny alcohol abuse.
After the interruption of the antiretroviral drugs, liver transaminases decreased, so that, on January 20th 2005, a new treatment with tenofovir (TDF), lamivudine (3TC) and nelfinavir (NFV) was initiated due to the lowering of the CD4+ T cells count. Despite the new treatment, between January 2005 and August 2006, the transaminase levels decreased significantly and remained just above the upper limit of normality.
This case suggests a relationship between antiretroviral therapy including d4T and hepatotoxicity. Some authors have suggested that acute liver enzyme elevation in HIV-positive patients is often due to previous conditions, rather than to antiretroviral therapy itself . Specifically, in patients with chronic viral hepatites coexistence, HAART-related HT develops more frequently or sooner, and also in a more severe form . In this group of patients, liver damage may also be caused by immune reconstitution and related exacerbation of viral hepatites . Actual drug-related hepatotoxicities may thus be confounded by the natural history of concomitant viral hepatites in these patients.
In vitro studies demonstrated the NRTI are able to inhibit mithocondrial DNA polymerase, DNA polymerase gamma in particular . Moreover, some cases of severe lactate elevation and liver steatosis during HAART including d4T have been reported . In the present case, an important transaminase elevation without lactate elevation was detected. A liver biopsy documented chronic aggressive hepatitis of a possible multifactorial etiology, including initial metabolic disorder with suspected signs of drug hepatotoxicity. Although the histological findings were not specific for drug-induced damage, other causes of liver damage, such as HCV or HBV co-infections, alcohol abuse, metabolic syndrome and assumption of concomitant hepatotoxic drugs were excluded. Therefore, this case report may be particularly relevant since pure drug-induced hepatotoxicity may be postulated, regardless of the "background" effect of chronic hepatitis co-infections. The mechanism of d4T toxicity may have been mediated by liver steatosis, which has already been associated with d4T and other ddX use [11, 12]. A steatotic liver, particularly if some grade of fibrosis is present, may be more susceptible to the toxic effect of the drugs. Therefore, use of PI boosted with low dose ritonavir could not be excluded as causative agent of the first episode of transaminase elevation. Although transaminase levels appeared to partially ameliorate after boosted-PI discontinuation, ALT levels always remained at least 3 times higher than the upper limit of normality and a second episode of grade III hepatotoxicity occurred during a NRTI-based regimen. Liver transaminases returned to rather normal values only when NRTIs other than d4T (TDF and 3TC) were administrated. Some authors have observed that switching to alternative NRTIs, such as TDF or abacavir, may reduce lipoatrophy or prevent recurrence of lactic acidosis . Our patient case suggests that a similar phenomenon may occur in the event of hepatotoxicity.
This case report underlines the importance of d4T as a possible causative agent of hepatotoxicity, even in the absence of other signs of mitochondrial toxicity. Liver biopsy may provide further important information regarding patients with severe transaminase elevation, in order to better assess the possible causative factors.
We gratefully thank the patient for consenting to the publication of this study.
We are very grateful to Dr. Ruth Bando who revised the English language.
- Nunez M: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006, 44: S132-S139. 10.1016/j.jhep.2005.11.027.View ArticlePubMedGoogle Scholar
- Velsor LW, Kovacevic M, Goldstein M, Leitner HM, Lewis W, Day BJ: Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol Appl Pharmacol. 2004, 199: 10-19. 10.1016/j.taap.2004.03.005.View ArticlePubMedGoogle Scholar
- Birkus G, Hitchcock MJ, Cihlar T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002, 46: 716-723. 10.1128/AAC.46.3.716-723.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- den BM, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van LR, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000, 14: 2895-2902. 10.1097/00002030-200012220-00011.View ArticleGoogle Scholar
- Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo CS, Di PG, Filice G, Tinelli C, Carosi G: Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis. 2005, 5: 58-10.1186/1471-2334-5-58.View ArticlePubMedPubMed CentralGoogle Scholar
- Livry C, Binquet C, Sgro C, Froidure M, Duong M, Buisson M, Grappin M, Quantin C, Portier H, Chavanet P, Piroth L: Acute liver enzyme elevations in HIV-1-infected patients. HIV Clin Trials. 2003, 4: 400-410. 10.1310/2L6M-EE7G-5PGN-FJYP.View ArticlePubMedGoogle Scholar
- Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000, 283: 74-80. 10.1001/jama.283.1.74.View ArticlePubMedGoogle Scholar
- Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F, Carosi G: Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr. 2003, 32: 259-267. 10.1097/00126334-200303010-00004.View ArticlePubMedGoogle Scholar
- Brinkman K, Kakuda TN: Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?. Curr Opin Infect Dis. 2000, 13: 5-11.View ArticlePubMedGoogle Scholar
- Cornejo-Juarez P, Sierra-Madero J, Volkow-Fernandez P: Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment. Arch Med Res. 2003, 34: 64-69. 10.1016/S0188-4409(02)00454-X.View ArticlePubMedGoogle Scholar
- McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, Schwartzapfel B, Rindler E, Fiorino AM, Zaman MT, Sax PE, Graeme-Cook F, Hibberd PL: Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006, 43: 365-372. 10.1086/505495.View ArticlePubMedGoogle Scholar
- Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL: Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005, 19: 585-592.View ArticlePubMedGoogle Scholar
- Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006, 20: 2043-2050. 10.1097/01.aids.0000247574.33998.03.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.